GemPharmatech's ambitious Knockout All Project (KOAP) aims to create knockout (KO) and conditional knockout (cKO) mouse strains for all ~23,000 protein coding genes in the mouse genome. Our specialized gene editing platform enables the production of over 6,000 new mutant strains annually, generating KO and cKO mice quickly and efficiently. To date, we have successfully targeted more than 11,500 genes, providing researchers with knockout mouse models and conditional knockout mouse models for a wide range of research fields, including oncology, autoimmunity, metabolism, and neurodegeneration. Our ultimate goal at GemPharmatech is to provide our customers with the best mouse tools to accelerate their biomedical discovery and drug development.
GemPharmatech has developed numerous disease mouse models using various modeling technologies, including transgenic (Tg), knockout (KO), and knockin (KI). These models can be utilized for disease-related research applications such as metabolism, tumors, immunology, and neurology.
Germ-free (GF) mice are laboratory animals that have no detected living organisms (including any microorganisms or parasites) internally or externally, based on the currently available detection methods.
Genetic engineering with the Cre-lox system is a powerful and indispensable method to unveil gene function, especially in model animals. GemPharmatech has generated more than 200 Cre and 9 Dre/DreER mouse strains which have been carefully designed for efficient and reliable Cre-mediated recombination in vivo.
Due to advancements in molecular biology techniques, the number of immunodeficient mouse strains has increased, playing a crucial role in fields such as immunology, oncology, stem cell biology, and infectious diseases. GemPharmatech has developed 26 severe immunodeficient mouse models for a wide range of scientific applications.
Wild mice, different from laboratory inbred mice, survive in natural habitats and must adapt to numerous environmental stressors, resulting in greater genetic diversity, including single nucleotide polymorphisms (SNPs), deletions, and duplication of genomic sequences. According to previous studies, wild mice have varying susceptibilities to infectious diseases and may better mimic humans for preclinical drug screening and adverse effect assessment.
Based on the fully human antibody transgenic mouse NeoMab platform, we have NeoMab-IgG mice (Standard IgG), NeoMab-CLC™ mice (Common Light Chain), and NeoMab-HC™ mice (Heavy Chain Only), which can produce various fully human modules such as IgG, ScFv, Fab, sdAb, and BsAb. This supports the development of a wide range of products for ADCs, AOCs, mono-/bi-/multi-specific antibodies, nanobodies and cell therapies.
